MS News: April 2014
Research results Enhanced uptake of multiple sclerosis-derived myelin by THP-1 macrophages and primary human … 7thSpace Interactive (press release) – The pathological hallmark of multiple sclerosis (MS) is myelin phagocytosis. It remains unclear why microglia and macrophages demyelinate axons in … Textured insoles could be a positive step for people with MS UQ News – University of Queensland research is investigating the effects textured shoe insoles have on walking problems associated with multiple sclerosis. ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis News-Medical.net – Antisense Therapeutics Limited (“ANP” or the “Company”) is pleased to advise that results from a chronic toxicity study in monkeys indicate that …
MS News: March 2014
A little bit later than usual, for which I apologise, but here is the good news that graced global media in March 2014.
MS news: February 2014
The positives so far… Relapsing-Remitting Multiple Sclerosis Drug Copaxone Gets FDA Approval For Bigger Dose, Fewer Injections BioNews Texas – Copaxone injection for relapsing-remitting multiple sclerosis There is new news regarding a widely-used treatment for Relapsing-Remitting Multiple Sclerosis. According to the latest reports released by Teva Pharmaceutical Industries, the FDA has approved the company’s concentrated 3-times-per-week formulations of Copaxone, and that the formulation will now be available in 40 mg dosages. Secondary Progressive MS Trial of Lamotrigine Tested For Neuroprotection Benefits BioNews Texas – The research team proposed that delaying nerve cell destruction can limit the rate of disability in secondary progressive MS patients. The supporting study, which was completed after two years of testing, was aimed at employing nerve cell blockers like lamotrigine to monitor the rate of worsening disability…
MS News: January 2014
Primary Progressive, Relapse-Free Secondary Progressive Multiple … BioNews Texas – secondary progressive multiple sclerosis nerve While there have been a number of success stories for MS research in 2013, last year saw yet another … Gov candidates cool to more marijuana legalization Kansas City Star – Most Republicans said it was too early to decide, but a Republican candidate for lieutenant governor who suffers from multiple sclerosis said it should …
MS News: December 2013
With a bit of a delay, here is the good news in MS-world that found its way to the media in December 2013! Provincial MS strategy applauded Announced Nov. 25, Health Minister Fred Horne said the strategy – The Way Forward – “connects the dots” in the health care system so that Alberta’s almost 14,000 multiple sclerosis (MS) patients can access resources and find supports more easily. Teva and Takeda Announce Agreement for Glatiramer Acetate for Multiple Sclerosis Treatment in Japan Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda Pharmaceutical Company Limited (Takeda) today announced the signing earlier this year of an agreement in which Teva licensed to Takeda the right to commercialize Teva’s innovative glatiramer acetate (active ingredient) formulation for the treatment of multiple sclerosis, in Japan. Teva and Takeda…
MS News: November 2013
Thirty pieces of positive MS news published in November to brighten your day! Multiple sclerosis appears to originate in different part of brain than long believed Steven Schutzer, a physician and scientist at Rutgers New Jersey Medical School, has now found an important clue why progress has been slow – it appears that most research on the origins of MS has focused on the wrong part of the brain.
MS News: October 2013
Childhood Stress Not a Likely Trigger for MS Stressful life events in childhood did not appear to increase the subsequent risk for multiple sclerosis (MS), researchers said. In large Danish cohort study, children who experienced stressful life events had a weak 1.11-fold risk (95% CI 1.02-1.20) of later developing MS compared with unexposed children, according to Nete Munk Nielsen, MD, PhD, from Statens Serum Institut in Copenhagen, and colleagues.